November 06, 2012 Tuesday - updated 13:01 PM PT

MissionIR Blog - Cardium Therapeutics, Inc. (CXM) Sees Opportunity Outside The U.S.

Atlanta, United States ( - November 06, 2012) When the FDA recently announced that it is considering a faster approval process for developers of drugs for serious diseases, it was important news for companies like Cardium Therapeutics, a San Diego-based health sciences and regenerative medicine developer. Development of a significant new drug is expensive and time consuming even without the regulatory requirements, and pressure has been mounting on the FDA to make the process more efficient. The goal of the new process is to allow quicker clinical trials, while also letting physicians administer the drugs to critical need patients where the benefits would outweigh the risks.

But pharmaceutical developers like Cardium are often not focused on the U.S. alone. Major markets can exist in other parts of the world where a given drug may fit special needs and conditions. In the case of Cardium, one of their lead products is Generx, a DNA-based angiogenic growth factor therapeutic designed to stimulate blood vessel growth around the heart. In places where costly and invasive surgical revascularization procedures, such as coronary artery bypass surgery and angioplasty/stents, may not be feasible, the kind of innovative and cost-effective treatment Generx represents is a good match.

It is expected that 80 percent of future increases in coronary heart disease will occur outside the United States, representing a significant opening for Cardium and Generx. Cardium CEO, Christopher Reinhard, recognizes the opportunity: “We believe that Generx may offer the potential for a one-time, non-surgical cost-efficient treatment option for patients with myocardial ischemia due to coronary artery disease.”

In June, Cardium announced that it had received clearance from the Russian Ministry of Health and Social Development to start the phase III registration study for Generx. The Russian Health Authority will brand Generx with the therapeutic drug trade name Cardionovo for purposes of marketing.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit

To connect with MissionIR via Facebook, please visit

To connect with MissionIR via Twitter, please visit

Please read FULL disclaimer on the MissionIR website:

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.



Media Contact:

Senior Editor
3645 Marketplace Blvd.
Atlanta, GA

Phone: 404-941-8975
creat you account

Terms of Service | Privacy Policy | Link to IBwire | Contact Us

Issuers of press releases and not IBwire are only accountable for the precision of the information they included.
If you have any inquiries or questions concerning the press release please contact the company directly listed in the press release.

© Copyright 2016, IBwire inc

submit press release | press release distribution | press release service